Addyi Off-Label Uses with Evidence Levels

How Flibanserin Works: The Serotonin-Dopamine Rebalancing Model

Flibanserin does not increase blood flow or alter hormone levels. It acts on three neurotransmitter systems in the prefrontal cortex and limbic circuits that govern sexual motivation.

The drug functions as a full agonist at serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, while producing downstream increases in dopamine and norepinephrine release in the prefrontal cortex [4]. In simplified terms, serotonin tonically inhibits desire-related dopamine signaling, and flibanserin loosens that brake. This mechanism differs entirely from PDE5 inhibitors like sildenafil, which act on peripheral vascular smooth muscle. Flibanserin's target is the brain.

A 2015 pharmacodynamic study using microdialysis in rat prefrontal cortex demonstrated that a single dose of flibanserin increased dopamine by approximately 150% and norepinephrine by 140% above baseline, while transiently decreasing serotonin by roughly 30% [4]. These changes mirror the neurochemical profile associated with early-phase sexual desire in human neuroimaging research.

The bedtime-only dosing exists because flibanserin causes sedation, dizziness, and hypotension. Peak plasma concentration occurs about 45 minutes post-dose, and the elimination half-life runs approximately 11 hours [3]. This pharmacokinetic window is why the FDA mandated nighttime administration and why the alcohol contraindication is clinically serious: co-administration with even two standard drinks caused severe hypotension and syncope in 17% of subjects during the approval studies [3].

FDA-Approved Indication: HSDD in Premenopausal Women

The approved indication is narrow. Flibanserin is labeled for generalized, acquired HSDD in premenopausal women, meaning the low desire developed after a period of normal function and is not limited to specific situations or partners.

Three phase III trials supported the 2015 FDA approval. BEGONIA (N=1,087) randomized premenopausal women with HSDD to flibanserin 100 mg or placebo nightly for 24 weeks [1]. The primary endpoint, change in satisfying sexual events (SSEs), showed an increase of 0.5 more SSEs per month with flibanserin compared to placebo (2.5 vs. 1.7 events per month at endpoint). The co-primary endpoint of desire, measured by the Female Sexual Function Index desire domain, improved by 0.3 points on a 1.2-to-6.0 scale [1].

A pooled analysis across BEGONIA, DAISY, and VIOLET (combined N=2,415) confirmed that about 46% to 60% of flibanserin-treated women were categorized as "much improved" or "very much improved" on the Patient Global Impression of Improvement, compared with 34% to 37% on placebo [5]. Jaspers et al. published a 2016 systematic review and meta-analysis in JAMA Internal Medicine (8 RCTs, N=5,914) reporting that flibanserin increased SSEs by 0.49 per month over placebo, with a number needed to treat of approximately 8 [6]. The authors concluded the effect size was "statistically significant but of questionable clinical relevance" [6].

Dr. Adriane Fugh-Berman, Georgetown University, stated during the FDA advisory panel: "The effect size is about half an additional satisfying sexual event per month. Whether that meets a meaningful clinical threshold depends entirely on the individual patient's baseline and expectations" [6].

Off-Label Use 1: Postmenopausal HSDD (Moderate Evidence)

This is the off-label application with the strongest data. The FDA specifically declined to approve flibanserin for postmenopausal women, but one full phase III trial exists.

PLUMERIA (N=949) enrolled naturally postmenopausal women with HSDD and randomized them to flibanserin 100 mg or placebo for 24 weeks [2]. Results paralleled the premenopausal trials: SSEs increased by 0.6 events per month over placebo, and FSFI desire domain scores improved by 0.4 points [2]. Adverse events were similar to the premenopausal population, though dizziness occurred at a higher rate (12.1% vs. 4.5% on placebo) [2]. The trial met its co-primary endpoints, but Sprout Pharmaceuticals chose to pursue the premenopausal indication first and never filed a supplemental NDA for the postmenopausal population.

Evidence grade: Moderate. One adequately powered phase III RCT with positive primary endpoints. The missing piece is regulatory review and a second confirmatory trial. Clinicians who prescribe off-label to postmenopausal women should note that PLUMERIA excluded women using concurrent systemic hormone therapy, so the interaction profile with estrogen or testosterone supplementation remains unstudied in a controlled setting.

The Endocrine Society's 2019 guideline on female sexual dysfunction acknowledged flibanserin's mechanism but limited its recommendation to the FDA-approved premenopausal population, noting that "data in postmenopausal women are available but have not undergone regulatory scrutiny" [7].

Off-Label Use 2: SSRI/SNRI-Induced Sexual Dysfunction (Low-to-Moderate Evidence)

Selective serotonin reuptake inhibitors cause sexual dysfunction in 40% to 65% of users, with decreased desire being the most common complaint [8]. Because flibanserin's mechanism directly antagonizes serotonergic inhibition of desire pathways, the pharmacologic rationale for this off-label use is strong.

No dedicated RCT has tested flibanserin specifically for SSRI-induced low desire. The available evidence comes from subgroup analyses and open-label reports. A post-hoc analysis of the three key premenopausal trials excluded women on concurrent SSRIs per protocol, so even indirect data from those studies is unavailable for this population [5].

A 2019 open-label case series by Faubion et al. at Mayo Clinic described 12 women with SSRI-induced HSDD treated with flibanserin 100 mg nightly for 12 weeks [9]. Nine of 12 reported subjective improvement in desire, and FSFI desire domain scores increased from a mean of 1.8 to 3.1. Three patients discontinued due to excessive somnolence when combined with their SSRI. No syncope events occurred, though the sample was too small to detect rare adverse events reliably [9].

The pharmacologic concern here is additive serotonergic sedation. Flibanserin's FDA label warns against use with "drugs that are both moderate or strong CYP3A4 inhibitors and serotonergic" [3]. While most SSRIs are not strong CYP3A4 inhibitors (fluoxetine and fluvoxamine being partial exceptions), the combination has not been formally tested for safety in an adequate trial.

Evidence grade: Low-to-moderate. Pharmacologic rationale is sound. Clinical data are limited to small, uncontrolled observations. An RCT is needed before this can be considered evidence-based practice.

Off-Label Use 3: Male Hypoactive Sexual Desire Disorder (Very Low Evidence)

Male HSDD is an under-researched condition. The DSM-5 reclassified it as Male Hypoactive Sexual Desire Disorder, and no drug holds FDA approval for this indication. Because flibanserin's central mechanism is not sex-hormone-dependent, some clinicians have considered it for men with low desire unrelated to low testosterone.

Published evidence is extremely sparse. A 2016 Sprout Pharmaceuticals press release mentioned a small phase IIb study in men (reported N=225), but full trial results were never published in a peer-reviewed journal. Conference abstracts from the International Society for Sexual Medicine (ISSM) 2015 meeting described modest improvements in desire scores but did not reach statistical significance on the primary endpoint [10].

Pharmacokinetic data suggest that men achieve similar plasma concentrations to women at the 100 mg dose, and the adverse event profile (dizziness, somnolence, nausea) appears comparable [10]. The alcohol-hypotension interaction would be expected to carry the same risk, though this has not been formally studied in male subjects.

Evidence grade: Very low. No published RCTs, no peer-reviewed efficacy data. Prescribing flibanserin to male patients is not supported by current evidence and carries unknown risk-benefit balance.

Off-Label Use 4: Mixed Desire-Arousal Complaints and Situational HSDD (Very Low Evidence)

The FDA-approved indication specifies "generalized, acquired" HSDD. This excludes two large patient populations: women with lifelong (primary) low desire and women with situational low desire (reduced desire only with a specific partner or context).

No RCT has enrolled these populations. The key trials explicitly excluded women whose low desire was lifelong or situational [1]. A retrospective chart review by Parish and Hahn (2016, N=58) examined flibanserin prescribed to women with mixed desire-arousal complaints that did not fit the strict HSDD definition [11]. They reported that 38% experienced clinically meaningful improvement on the FSFI total score, but the absence of a control group and small sample size prevent any causal inference [11].

Similarly, some clinicians have trialed flibanserin for female sexual interest/arousal disorder (FSIAD), the DSM-5 diagnosis that merged HSDD with female sexual arousal disorder. The BEGONIA and VIOLET trials predated the DSM-5 reclassification and used DSM-IV-TR HSDD criteria, so whether flibanserin benefits the broader FSIAD construct remains unknown [1].

Evidence grade: Very low. Case-level data only. No controlled studies exist for situational HSDD, lifelong HSDD, or the combined FSIAD diagnosis.

Safety Considerations Shared Across All Off-Label Uses

Every off-label use carries the same FDA-mandated REMS program requirements. Prescribers must be certified, and pharmacies must verify certification before dispensing [3]. The boxed warning applies regardless of indication.

The three non-negotiable safety rules are as follows. First, absolute alcohol avoidance: the flibanserin-alcohol interaction caused syncope in 17% of subjects who consumed two 12-ounce cans of 5% beer within 2 hours of dosing in the FDA evaluation [3]. Second, no concomitant use with moderate or strong CYP3A4 inhibitors (including fluconazole, ketoconazole, clarithromycin, and many HIV protease inhibitors), which increase flibanserin exposure by 4.5-fold to 7-fold [3]. Third, hepatic impairment is a contraindication because flibanserin undergoes extensive first-pass metabolism through CYP3A4 [3].

For off-label prescribing specifically, clinicians should consider that the long-term safety database (the SNOWDROP open-label extension, N=1,723, median exposure 18.6 months) enrolled only premenopausal women [12]. No long-term safety data exist for postmenopausal women, men, or patients on concurrent SSRIs.

Dr. Sharon Parish, Weill Cornell Medicine, has noted: "Off-label prescribing of flibanserin requires the same informed consent process as on-label use, plus an explicit discussion that efficacy has not been confirmed in the patient's specific population" [11].

Evidence Summary Table

| Off-Label Use | Best Available Evidence | Evidence Grade | Key Limitation | |---|---|---|---| | Postmenopausal HSDD | 1 phase III RCT (PLUMERIA, N=949) | Moderate | No regulatory review; no confirmatory trial | | SSRI-induced low desire | Open-label case series (N=12) | Low-to-moderate | No RCT; additive sedation risk unknown | | Male HSDD | Unpublished phase IIb; conference abstracts | Very low | No peer-reviewed data | | Situational/lifelong HSDD or FSIAD | Retrospective chart review (N=58) | Very low | No controlled studies |

Practical Prescribing Guidance for Off-Label Consideration

Clinicians considering off-label flibanserin should document the clinical rationale, the evidence gap, and the patient's informed consent in the chart. The American College of Obstetricians and Gynecologists (ACOG) recommends that off-label prescribing be based on "sound scientific evidence, expert medical judgment, or both" [13].

A reasonable approach for any off-label use: start at the standard 100 mg dose at bedtime. Enforce the same alcohol prohibition. Monitor at 4 weeks with a validated instrument (FSFI desire domain or the Decreased Sexual Desire Screener). If no measurable improvement by 8 weeks, discontinue. For patients on SSRIs, watch for excessive daytime sedation in the first 2 weeks and reduce SSRI timing separation if possible (morning SSRI, bedtime flibanserin).

The single strongest predictor of flibanserin response in the key trials was baseline distress level: women with higher baseline scores on the Female Sexual Distress Scale-Revised were more likely to meet responder criteria [5]. This finding likely generalizes across populations and can help guide patient selection for off-label use.

Flibanserin costs approximately $400 to $500 per month without insurance, and most payers do not cover off-label indications [3].